2 Upgraded Drug Stocks Squeezing Shorts

Janney said to buy TTOO stock after earnings

May 9, 2018 at 10:21 AM
facebook twitter linkedin


T2 Biosystems Inc (NASDAQ:TTOO) was upgraded to "buy" from "neutral" at Janney, after the sepsis specialist reported first-quarter revenue of $2.3 million -- well above the consensus estimate of $1.4 million. Leerink also chimed in, boosting its price target to $5 from $4 -- though this is still a discount to last night's close at $6.10. Nevertheless, TTOO stock is up 7.5% today to trade at $6.56.

Longer term, the shares are up nearly 63% year-to-date, with pullbacks contained by double-barreled support from TTOO's 80-day and 200-day moving averages. The surging stock seems ripe for a short squeeze, too. Short interest on T2 Biosystems is up 76% from the Feb. 15 reporting period to 1.62 million shares. This represents 8.1% of the security's available float, and would take nearly eight days to cover, at the average pace of trading.

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) also received bullish brokerage attention after the biopharmaceutical firm reported a slimmer-than-expected fiscal second-quarter loss. Specifically, Cantor Fitzgerald upgraded ARWR stock to "overweight" from "neutral," and raised its price target to $13 from $5 -- territory not charted since October 2014.

The brokerage firm waxed optimistic on the company's transition back into the clinical business. Cantor Fitzgerald also said it is upbeat about ARWR's growing pipeline, which includes upcoming clinical trial applications for its cystic fibrosis and renal cell carcinoma treatments.

At last check, ARWR stock is up 19.5% to trade at $9.26 -- breaking through previous congestion in the $8 region to hit a three-year high of $9.60. The shares are now up more than 147% in 2018 on support from their 50-day and 80-day moving averages, and short sellers are likely spooked. The 6.60 million ARWR shares sold short represent 10% of the stock's float, or 5.2 days' worth of pent-up buying demand, at the average pace of trading.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Best stocks for October and worst stocks for October
 


 


 
Special Offers from Schaeffer's Trading Partners